HRV Pharma has announced a strategic partnership with Shodhana Laboratories to accelerate the development of next-generation active pharmaceutical ingredients (APIs). This collaboration brings together HRV’s AI-enabled virtual pharmaceutical platform with Shodhana’s deep expertise in precision chemistry and GMP manufacturing.
The partnership marks a significant step in advancing high-value, complex APIs aligned with global regulatory standards, including US Drug Master Files (DMFs), while supporting innovation in longevity biology and precision medicine.
Advancing Next-Generation API Development
This collaboration integrates HRV Pharma’s global market access and regulatory execution capabilities with Shodhana Laboratories’ advanced process chemistry and manufacturing infrastructure.
- Development and US DMF filing for pharmaceutical-grade APIs
- Focus on longevity biology and precision medicine applications
- Integration of AI-enabled virtual API development platforms
- End-to-end development from synthesis to commercialization
This approach enables faster development timelines while maintaining strict regulatory and quality standards required for global markets.
Strategic Scope and Capabilities
Under the multi-year agreement, both companies will jointly execute a structured development and commercialization strategy across regulated markets.
- Pipeline of high-science APIs across oncology, CNS, rare diseases, and metabolic disorders
- Global regulatory filings aligned with US FDA, EMA, and other international agencies
- Comprehensive CMC documentation, validation, and stability programs
- Supply chain coordination and commercial execution across multiple regions
The partnership is designed to support pharmaceutical innovators by delivering complex APIs with regulatory clarity and scalable manufacturing readiness.
Leadership Perspective
The collaboration reflects a shared vision to build future-ready pharmaceutical capabilities.
"The API landscape is evolving beyond traditional categories. Filing US DMFs for high-science APIs signals a shift toward the next decade of pharmaceutical innovation. By combining precision chemistry with global regulatory execution, we are building a platform that defines the future of API development."
- Hari Kiran Chereddi, Managing Director & CEO, HRV Pharma
Shodhana Laboratories also emphasized the importance of combining scientific precision with global reach to enable high-quality API manufacturing for regulated markets.
Driving Innovation Through Collaboration
The partnership has already initiated multiple development programs, with both organizations working within a milestone-driven framework to accelerate execution.
By leveraging AI-enabled platforms, GMP manufacturing excellence, and global regulatory alignment, HRV Pharma and Shodhana Laboratories aim to unlock new possibilities in complex molecule development.
Looking Ahead
This collaboration reinforces HRV Pharma’s mission to build an asset-light, technology-driven pharmaceutical platform that connects innovation, manufacturing, and global market access.
As demand for precision therapies and complex APIs continues to grow, partnerships like this will play a critical role in shaping the future of pharmaceutical development.
Media Coverage
This strategic partnership between HRV Pharma and Shodhana Laboratories has received extensive coverage across leading pharmaceutical and business publications:
- Express Pharma
- Pharmabiz
- BioSpectrum India
- Medgate Today
- APN News
- Passionate in Marketing
- India Education Diary
- PNI News
Frequently Asked Questions
What is the HRV Pharma and Shodhana partnership about?
This is a strategic collaboration to develop next-generation APIs by combining HRV Pharma’s virtual platform and regulatory expertise with Shodhana’s precision chemistry and GMP manufacturing capabilities.
What types of APIs are being developed?
The partnership focuses on high-value, complex APIs across oncology, CNS disorders, rare diseases, and metabolic conditions.
What is the role of AI in this collaboration?
HRV Pharma’s AI-enabled virtual platform helps streamline API development, optimize processes, and improve regulatory execution across global markets.
What regulatory markets are targeted?
The collaboration supports filings across major regulated markets including the United States (US DMF), Europe (EMA), and other international jurisdictions.
Why is this partnership important for the pharma industry?
It enables faster development of complex APIs, improves regulatory readiness, and supports global access to advanced therapies through scalable and compliant manufacturing.
